Michael Charlton to Recombinant Proteins
This is a "connection" page, showing publications Michael Charlton has written about Recombinant Proteins.
Connection Strength
0.553
-
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
Score: 0.113
-
A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9(8):1707-13.
Score: 0.074
-
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33.
Score: 0.070
-
Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
Score: 0.060
-
Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis. 2004; 24 Suppl 2:79-88.
Score: 0.051
-
Pre-emptive treatment of recurrent hepatitis C infection. Liver Transpl. 2002 Oct; 8(10 Suppl 1):S50-4.
Score: 0.047
-
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
Score: 0.046
-
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
Score: 0.045
-
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
Score: 0.024
-
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
Score: 0.021